In 2022, ChatGPT amazed millions with its abilities but also had some strange quirks. Now, GPT-4 is here, smarter and more accurate, poised to revolutionize medicine. This book explores what AI can and can’t do, its ethical boundaries, and real-life applications. Insider perspectives reveal its potential in diagnoses, patient interactions, research, and more. You’ll encounter unfiltered GPT-4 dialogues, learn about trust-building, patient empowerment, cost reduction, and regulatory insights. Discover AI’s impact on healthcare and be prepared for its transformative effects, whether you’re a healthcare professional, patient, or policymaker.
Since the rollout of ChatGPT in November 2022, the debate on artificial intelligence (AI) and its impact on humanity has intensified. In an instant, ChatGPT appears to have reshaped the world as we know it, but AI has been steadily evolving since its inception in 1957. Its profound and lasting implications across all industries, from entertainment to healthcare to education and elsewhere, are palpable for everyone with varying degrees of tech proficiency. While experts grapple with whether AI is a Pandora’s Box or a panacea, there is a clear consensus that it stands as one of the monumental human inventions comparable to the internet and electricity. The revolutionary power of AI to transform lives is both awe-inspiring and daunting at once.
AI’s most significant application became evident in the realm of medicine and pharmaceuticals. In 2023, Peter Lee, corporate vice president of Microsoft Healthcare; Carey Goldberg, a longstanding medical and science journalist; and Isaac Kohane, MD, PhD, professor at the Department of Biomedical Informatics at Harvard University, collaborated to publish “The AI Revolution in Medicine: GPT-4 and Beyond.” The book provides a fascinating overview of early observations and experiences with what is now known as GPT-4, a multimodal large language model (LLM) created by OpenAI in its fourth series of GPT foundation models. The use of AI has propelled groundbreaking research and innovations in healthcare, employing LLMs – a type of AI algorithm utilizing deep learning techniques and extensive datasets to swiftly understand, summarize, generate, and predict new content. For example, it is unthinkable to consider cost-effective drug discovery and development today without incorporating AI into the process. The powerful impact of this technology on physicians and patients alike could mean the difference between life and death in some cases. How will this technology revolutionize healthcare? Can we trust its output? Drawing from the authors’ conversations with GPT-4, the book explores the fundamentals of LLM and machine learning, delving into AI’s capabilities and opportunities in basic medical quests, including its aid in diagnosis and clinical notes. It also addresses the pitfalls of endless data capture, ethical concerns, and the lack of regulatory compliance processes.
“Medicine traditionally refers to a sacred relationship between a doctor and a patient — a twosome, a dyad. “And I’m proposing that now we move to a triad,” he said, with an AI entity like GPT-4 as the third leg of that triangle.”
The book asserts that the potential of AI is genuinely life-altering. As technology continues to advance, envisioning an empathetic AI physician by our bedside isn’t far-fetched. Featuring Sam Altman, Kevin Scott, and others who are today’s influential voices in AI, the authors paint an optimistic outlook for AI in medicine, while offering food for thought as humanity stands at the precipice of an enormous crossroad with the wide deployment of AI and LLMs, prompting contemplation on our future in medicine and beyond.
January 8, 2024
Sabina Lee, M.A.
Senior Consultant, W Medical Strategy Group
Building on her international experience, she helps clients navigate complex issues management and cross-cultural PR and marcomms in the global environments. She has worked with a range of clients in varied sectors, including high-profile institutions, government agencies and corporations in New York, Washington D.C., Beijing, Paris and Seoul. Sabina previously served as chief media strategist for the Pulitzer Prizes and senior public affairs officer for Cornell and Columbia Universities. A graduate of Pratt Institute in New York, she attended the Middlebury Institute of International Studies in California for her M.A. in International Policy and Development.